30 Day Trial

Biologica Technologies Presents Update on ProteiOS Growth Factor


Biologica Technologies is debuting initial clinical data from spinal applications using its ProteiOS® growth factor derived from minimally manipulated allogeneic bone marrow. ProteiOS comprises angiogenic, mitogenic and osteoinductive proteins and what is reportedly the highest amount of non-recombinant BMP-2, and is designed for use with a surgeon's preferred FDA-cleared scaffold.

ProteiOS entered limited launch in 4Q17, and is now available throughout the U.S. 

Sources: Biologica Technologies, LLC; ORTHOWORLD Inc.